SWEDISH PATENT COURT UPHOLDS ASTRAZENECA OMEPRAZOLE SPC
21-Feb-2001
AstraZeneca today announced that
the Swedish Court of Patent Appeal has ruled that one of the company's Supplementary
Protection Certificates (SPC) in Sweden for omeprazole, the active ingredient in Losec®,
has not expired. The SPC expires in February, 2003.
The outcome reverses a decision from February 2000 by the Swedish Patent and
Registration Office (PRV) that the SPC, granted under Swedish law, had lapsed due to the
surrender of the marketing authorisation for Losec® capsules.
In 2000 Losec MUPS® sales in Sweden represented just over 1 per cent of the
total sales of the product.
The substance patent for omeprazole in Sweden expired in April 1999. Following the
decision by PRV to invalidate the omeprazole SPC, the generic manufacturer Scand Pharm
launched a generic product in Sweden. AstraZeneca filed a request for a preliminary
injunction against Scand Pharm for infringement of AstraZeneca's other Swedish SPC
relating to omeprazole. This SPC was granted under the EU regulation. The injunction was
granted, and later confirmed by the Stockholm District Court after the main hearing in
October 2000. Scand Pharm's product is therefore prohibited from sale pending the final
outcome of the case.
AstraZeneca has also filed a main action for infringement of the omeprazole formulation
patent.
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
